ES2180737T3 - Conjugado para la dosificacion individual de medicamentos, su procedimiento de preparacion y su uso en los mismos. - Google Patents

Conjugado para la dosificacion individual de medicamentos, su procedimiento de preparacion y su uso en los mismos.

Info

Publication number
ES2180737T3
ES2180737T3 ES96903881T ES96903881T ES2180737T3 ES 2180737 T3 ES2180737 T3 ES 2180737T3 ES 96903881 T ES96903881 T ES 96903881T ES 96903881 T ES96903881 T ES 96903881T ES 2180737 T3 ES2180737 T3 ES 2180737T3
Authority
ES
Spain
Prior art keywords
medicines
conjugated
same
preparation procedure
individual dosage
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES96903881T
Other languages
English (en)
Inventor
Hannsjorg Sinn
Wolfgang Maier-Borst
Hans-Hermann Schrenk
Gerd Stehle
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Deutsches Krebsforschungszentrum DKFZ
Original Assignee
Deutsches Krebsforschungszentrum DKFZ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Deutsches Krebsforschungszentrum DKFZ filed Critical Deutsches Krebsforschungszentrum DKFZ
Application granted granted Critical
Publication of ES2180737T3 publication Critical patent/ES2180737T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/136—Amines having aromatic rings, e.g. ketamine, nortriptyline having the amino group directly attached to the aromatic ring, e.g. benzeneamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/547—Chelates, e.g. Gd-DOTA or Zinc-amino acid chelates; Chelate-forming compounds, e.g. DOTA or ethylenediamine being covalently linked or complexed to the pharmacologically- or therapeutically-active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/081—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins the protein being an albumin, e.g. human serum albumin [HSA], bovine serum albumin [BSA], ovalbumin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)

Abstract

LA INVENCION TRATA DE UN CONJUGADO QUE COMPRENDE UNA SUSTANCIA ACTIVA Y UN COMPUESTO QUE MUESTRA UN PUNTO DE ENLACE CON COMPUESTOS METALICOS. LA INVENCION TRATA ADEMAS DE UN PROCEDIMIENTO PARA LA FABRICACION DE DICHO CONJUGADO Y SU USO.
ES96903881T 1995-02-21 1996-02-21 Conjugado para la dosificacion individual de medicamentos, su procedimiento de preparacion y su uso en los mismos. Expired - Lifetime ES2180737T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19505960A DE19505960A1 (de) 1995-02-21 1995-02-21 Konjugat zur individuellen Dosierung von Arzneimitteln

Publications (1)

Publication Number Publication Date
ES2180737T3 true ES2180737T3 (es) 2003-02-16

Family

ID=7754621

Family Applications (1)

Application Number Title Priority Date Filing Date
ES96903881T Expired - Lifetime ES2180737T3 (es) 1995-02-21 1996-02-21 Conjugado para la dosificacion individual de medicamentos, su procedimiento de preparacion y su uso en los mismos.

Country Status (8)

Country Link
US (1) US6410695B1 (es)
EP (1) EP0810883B1 (es)
JP (1) JPH11500134A (es)
AT (1) ATE221391T1 (es)
DE (2) DE19505960A1 (es)
DK (1) DK0810883T3 (es)
ES (1) ES2180737T3 (es)
WO (1) WO1996025956A2 (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2291066A1 (en) * 1998-03-23 1999-09-30 Conjuchem, Inc. Local delivery of long lasting therapeutic agents
US6740756B1 (en) 1998-07-07 2004-05-25 Smithkline Beecham Corporation Fluorescent lanthanide chelates
JP2002519404A (ja) * 1998-07-07 2002-07-02 スミスクライン・ビーチャム・コーポレイション 新規蛍光ランタニドキレート
DE19847362A1 (de) * 1998-10-14 2000-04-20 Deutsches Krebsforsch Makromolekulare Wirkstoffkonjugate und Verfahren zu ihrer Herstellung
AUPP856399A0 (en) * 1999-02-08 1999-03-04 Australian Membrane And Biotechnology Research Institute Improved compounds for protein binding
GB9929801D0 (en) * 1999-12-16 2000-02-09 Btg Int Ltd Anti-cancer agents iii
DE602005025659D1 (es) * 2004-09-23 2011-02-10 Guerbet Sa
US8986650B2 (en) 2005-10-07 2015-03-24 Guerbet Complex folate-NOTA-Ga68
JP5368099B2 (ja) * 2005-10-07 2013-12-18 ゲルベ ガリウムと錯体形成することが可能なシグナル部分にカップリングされた、生物学的標的の認識のための部分を含んでなる化合物
FR2942227B1 (fr) 2009-02-13 2011-04-15 Guerbet Sa Utilisation de tampons pour la complexation de radionucleides
FR2968999B1 (fr) 2010-12-20 2013-01-04 Guerbet Sa Nanoemulsion de chelate pour irm
FR2980364B1 (fr) 2011-09-26 2018-08-31 Guerbet Nanoemulsions et leur utilisation comme agents de contraste
FR3001154B1 (fr) 2013-01-23 2015-06-26 Guerbet Sa Magneto-emulsion vectorisee
FR3061713B1 (fr) * 2017-01-11 2020-02-14 Universite D'orleans Complexes de lanthanides a base de derives d'acide triethylenetetramine-n,n,n',n'',n''',n'''-hexaacetique
WO2020007822A1 (en) 2018-07-02 2020-01-09 Conservatoire National Des Arts Et Metiers (Cnam) Bismuth metallic (0) nanoparticles, process of manufacturing and uses thereof

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2551480C3 (de) * 1975-11-15 1982-04-22 Hoechst Ag, 6000 Frankfurt Technetium-99m-markiertes Nierendiagnostikum und Verfahren zu seiner Herstellung
US4339426A (en) * 1980-03-18 1982-07-13 Regents Of The University Of California Bleomycin analog
NL194579C (nl) * 1983-01-21 2002-08-05 Schering Ag Diagnostisch middel.
US4663277A (en) * 1983-05-20 1987-05-05 Profile Diagnostic Sciences Inc. Virus detection method and materials
DE3404443A1 (de) * 1984-02-08 1985-08-08 Hartmut Prof. Dr. 1000 Berlin Köpf Metallicenium-salze und deren verwendung als cytostatica bei der krebsbekaempfung
US4634586A (en) * 1984-05-21 1987-01-06 The Board Of Trustees Of The Leland Stanford Junior University Reagent and method for radioimaging leukocytes
US4837003A (en) * 1984-09-13 1989-06-06 Mallinckrodt, Inc. Radiolabeled antibody fragments
US4659839A (en) * 1984-10-10 1987-04-21 Mallinckrodt, Inc. Coupling agents for radiolabeled antibody fragments
CA1336076C (en) * 1985-01-14 1995-06-27 Alan R. Fritzberg Metal radionuclide labeled proteins for diagnosis and therapy
CA1282069C (en) * 1985-09-12 1991-03-26 Damon L. Meyer Antibody complexes of hapten-modified diagnostic or therapeutic agents
GB8610551D0 (en) * 1986-04-30 1986-06-04 Hoffmann La Roche Polypeptide & protein derivatives
EP0274343A1 (en) * 1987-01-06 1988-07-13 IntraCel Corporation A system of reactants involving an apo-enzyme useful in immunological analysis and a method for carrying out immunoassays with this system
WO1989000062A1 (en) * 1987-07-07 1989-01-12 The Cancer Institute Board Radiotherapy
WO1989005853A1 (en) * 1987-12-15 1989-06-29 Synthetic Genetics Nucleic acid chelate conjugate as therapeutic and diagnostic agents
DE68923274T2 (de) * 1988-02-09 1995-11-09 Mallinckrodt Inc Verfahren zur herstellung eines mit metall-radionuklid-markierten proteins.
CA1340527C (en) * 1988-05-31 1999-05-04 Lidia Vallarino Macrocyclic complexes of yttrium, the lanthanides and the actinides having peripheral coupling functionalities
US5094950A (en) * 1988-06-07 1992-03-10 Nihon Medi-Physics Co., Ltd. Diethylenetriamine pentaacetic acid derivatives
IE67273B1 (en) * 1988-06-24 1996-03-20 Dow Chemical Co Macrocylic bifunctional chelants complexes thereof and their antibody conjugates
US5101041A (en) * 1989-04-26 1992-03-31 The Curators Of The University Of Missouri Triamines and their derivatives as bifunctional chelating agents
EP0436005B1 (en) * 1989-07-20 1995-03-29 Sandoz Ltd. Labeled polypeptide derivatives
US5124471A (en) * 1990-03-26 1992-06-23 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Bifunctional dtpa-type ligand
US5367080A (en) * 1990-11-08 1994-11-22 Sterling Winthrop Inc. Complexing agents and targeting radioactive immunoreagents useful in therapeutic and diagnostic imaging compositions and methods
US5439829A (en) * 1991-01-30 1995-08-08 Eli Lilly And Company Immobilization of biologically active molecules by changing the Oxidation state of a chelated transition metal ion
US5310539A (en) * 1991-04-15 1994-05-10 Board Of Regents, The University Of Texas System Melanin-based agents for image enhancement
JPH0616561A (ja) * 1991-07-09 1994-01-25 Tsumura & Co 抗レトロウイルス剤
CA2113206A1 (en) * 1991-07-15 1993-02-04 Theodore E. Maione Modified pf4 compositions and methods of use
EP0596011A1 (en) * 1991-07-19 1994-05-11 Hybritech Incorporated Trifunctional compounds having specificity for multi-drug resistant cells
DE4134158C2 (de) * 1991-10-11 1997-02-13 Max Delbrueck Centrum Verwendung von Carboplatin in lyotrophen Mesophasen zur Überwindung einer durch Zytostatika ausgelösten Leukopenie
US5326778A (en) * 1992-03-03 1994-07-05 Research Corporation Technologies, Inc. Conjugates of biotin and deferoxamine for radioimmunoimaging and radioimmunotherapy
WO1993018160A1 (en) 1992-03-11 1993-09-16 Kenneth Francis Prendergast Anti-viral fusion peptides
US5292938A (en) * 1992-04-13 1994-03-08 Associated Universities, Inc. Synthesis of 4-substituted-trans-1, 2-diaminocyclohexyl polyaminocarboxylate metal chelating agents for the preparation of stable radiometal antibody immunoconjugates for therapy and spect and pet imaging
CA2135059A1 (en) * 1992-05-07 1993-11-11 John L. Toner Complexing agents and targeting immunoreagents
GB2268494B (en) * 1992-07-08 1996-08-21 Kenneth Francis Prendergast Imaging compositions
DE69327659T2 (de) 1992-10-14 2000-09-21 Nycomed Imaging As, Oslo Therapeutische und diagnostische bilderzeugungzusammensetzung und verfahren zur herstellung
DE69530375T2 (de) 1994-01-24 2004-02-05 Neorx Corp., Seattle Radioaktiv-markierte annexine
WO1995029707A1 (en) * 1994-04-29 1995-11-09 Center For Molecular Medicine And Immunology Composition for delivery of toxic radioisotopes to the cell nucleus and use
DE4435087A1 (de) 1994-09-30 1996-04-04 Deutsches Krebsforsch Konjugat zur Behandlung von Infektions-, Autoimmun- und Hauterkrankungen

Also Published As

Publication number Publication date
DE19505960A1 (de) 1996-08-22
WO1996025956A2 (de) 1996-08-29
JPH11500134A (ja) 1999-01-06
EP0810883A2 (de) 1997-12-10
WO1996025956A3 (de) 1996-12-27
EP0810883B1 (de) 2002-07-31
DE59609508D1 (de) 2002-09-05
ATE221391T1 (de) 2002-08-15
US6410695B1 (en) 2002-06-25
DK0810883T3 (da) 2002-11-11

Similar Documents

Publication Publication Date Title
ES2180737T3 (es) Conjugado para la dosificacion individual de medicamentos, su procedimiento de preparacion y su uso en los mismos.
BR9912975A (pt) Composto e composições para liberação de agentes ativos, método para sua obtenção e seu uso
EE200000320A (et) Uudsed ühendid
SE9704544D0 (sv) Novel compounds
ES2144192T3 (es) Nuevos derivados de 1-fenil-2-dimetil-amino-metil-ciclohexan-1-ol, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen.
BRPI9915822B8 (pt) derivados de pirazolopirimidinona e sua composição farmacêutica para o tratamento de impotência
BR9609738A (pt) Composições para aplicação de droga para estabilidade melhorada de esteróides
BR9610248A (pt) Composto composição farmacêutica processos para o tratamento da dor e para a preparação de um composto e uso do composto
BR9607862A (pt) Composição farmacêutica filmogênica para administração transdérmica
EE9500064A (et) Asendatud 1H-imidasoolid, nende valmistamismeetodid ja farmatseutilised kompositsioonid
SE9704546D0 (sv) Novel compounds
AR008991A1 (es) Compuestos de dimetil-(3-aril-but-3-enil)-amina, procedimientos para su preparacion y aplicacion de los mismos
BR9808422B1 (pt) composto, composiÇço farmacÊutica, uso de um composto, e, processo para a preparaÇço de um composto.
ES2221950T3 (es) Dihidrobenzofurano y compuestos relacionados utiles como agentes anti-inflamatorios.
ECSP930933A (es) Composicion farmaceutica y procedimiento para prepararla
ITMI962385A0 (it) Diaril-ciclometilenpirazoli farmacologicamente attivi procedimento per prepararli e composizioni farmaceutiche che li contengono
BR9602025A (pt) Composto composição farmacêutica uso e processo para a preparação de um composto
PT1107793E (pt) Conjugados de dextrano-leptina, composicoes farmaceuticas e processos relacionados
RU94040150A (ru) Стабильная лиофилизированная композиция тиотепа, способ ее получения
EE03996B1 (et) Farmatseutilised kompositsioonid, nende valmistamismeetod ja kasutamine
EE9400296A (et) Piperidinüültioindooli derivaadid, ravimvormid, aktiivne valuvaigisti, nende valmistamise meetodid
ATE353224T1 (de) Abgabeeinrichtung für eine zusammensetzung einer pharmazeutisch wirksamen substanz
AR002191A1 (es) Composicion farmaceutica oral de compuestos de piperidinoalcanol en forma de solucion, procedimiento para su preparacion
SE9403137D0 (sv) Derivatives of carbohydrates and compositions containing them
CL2003002750A1 (es) Compuestos derivados de carboxamidas ciclicas carboxi sustituidas, composicion farmaceutica, procedimiento de preparacion, utiles para preparar un medicamento para tratar la bronquitis y la tos.